Not FDA-approved
Bones & muscles
Sermorelin
Evidence
Limited human data
Class
Growth hormone-releasing hormone fragment
KEY TAKEAWAY
Sermorelin is a synthetic fragment made of the first 29 amino acids of growth hormone-releasing hormone. Sermorelin (Geref) was FDA-approved but was withdrawn from the market in 2008 for commercial reasons. There is no FDA-approved sermorelin product today.
Written by the Veylo editorial team · Updated
November 2026
What it is
Growth hormone-releasing hormone fragment
Main uses
Previously used to diagnose and treat growth hormone deficiency; now used off-label in anti-aging clinics
Key fact
Sermorelin (Geref) was FDA-approved but was withdrawn from the market in 2008 for commercial reasons. There is no FDA-approved sermorelin product today.
Route
Daily subcutaneous injection
Evidence strength
Limited human data
Sermorelin is a synthetic fragment made of the first 29 amino acids of growth hormone-releasing hormone.
It stimulates the pituitary gland to release growth hormone in a pulsed, natural pattern.
Sermorelin (Geref) was FDA-approved but was withdrawn from the market in 2008 for commercial reasons. There is no FDA-approved sermorelin product today.
Previously used to diagnose and treat growth hormone deficiency; now used off-label in anti-aging clinics.
Flushing, headache, injection-site reactions and dizziness were reported. Evidence for anti-aging benefits is weak.
Sermorelin: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.